The Latest Cardiac and Vascular News
Lesa brings 30 years of experience in marketing, product management, operations and sales to further diversify CardieX’s range of board members IRVINE, Calif., April 28, 2022 /PRNewswire/ — CardieX Limited (ASX: CDX), a global health technology company focused on cardiovascular disease and vascular health disorders, is pleased to announce the appointment of Lesa Musatto to its Board […]
SAN FRANCISCO, April 28, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that Mintu Turakhia, M.D. M.A.S., will join iRhythm in the new role of Chief Medical Officer and Chief Scientific Officer. Dr. […]
BURLINGTON, Mass., April 28, 2022 (GLOBE NEWSWIRE) — LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2022 results, announced a $0.125/share quarterly dividend and provided guidance. Q1 2022 Financial Results Sales of $39.6mm, +10% (+13% organic) vs. Q1 2021 Op. income of $7.9mm, +0% Op. margin of […]
WAYNE, Pa., April 28, 2022 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 27, 2022. First quarter financial summary Revenues of $641.7 million, up 1.2% year-over-year; up 3.2% on a constant currency basis GAAP diluted EPS from continuing operations of $1.63, […]
~ 1Q22 sales and profit consistent with expectations ~ ~ 2022 outlook updated for Aran Biomedical acquisition ~ PLANO, Texas, April 28, 2022 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced results for the three months ended April 1, 2022. First Quarter 2022 Highlights (compared […]
PARIS, April 28, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products that act directly on the brain in order to address difficult-to-treat/resistant hypertension and heart failure, today reported its full year 2021 results. […]
− Achieved First Quarter 2022 Global Net Product Revenues of $187 Million for ONPATTRO®, GIVLAARI®, and OXLUMO® – − Reported Positive 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy – − Announced 3-Month Extension of Review Period for New Drug Application for Vutrisiran due […]
First-quarter revenue of $3.7 billion increased 26% on a reported basis, 29% on a constant currency basis and 3% on an operational basis1 First-quarter U.S. GAAP earnings per share (EPS) totaled $0.14; Adjusted EPS totaled $0.93 Baxter expects full-year 2022 sales growth of 23% to 24% on a reported basis, […]
FY 2022 Annual Revenue of $1.032 billion, Up 22% Versus Prior Year DANVERS, Mass.–(BUSINESS WIRE)–ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 2022. Financial summary and operational highlights: Revenue for the […]
MARLBOROUGH, Mass., April 27, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis and 9.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income […]
